Decision: Cephalon, Inc. v. Slayback Pharma
LLC, No. 1:17-cv-01154 (D. Del. April 27, 2020).
Holding: Judge Connolly in the District of
Delaware decided that all of Cephalon's asserted claims are
valid and infringed.
Patents: 9,265,831; 9,572,797; 9,144,568;
9,597,399; 9,572,887
Background: Cephalon sued ANDA filers for
infringement of claims related to Bendeka®, a liquid
formulation of bendamustine for treatment of chronic lymphocytic
leukemia (CLL) and non-Hodgkin's lymphoma (NHL). Defendants
unsuccessfully argued that the asserted formulation claims were
invalid for obviousness, indefiniteness, lack of enablement and
lack of written description. Defendants further unsuccessfully
argued that the administration claims were invalid for
obviousness.